U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06819293) titled 'IB-T101 Injection for Treatment of Patients with Advanced Clear Cell Renal Cell Carcinoma' on Feb. 05.
Brief Summary: This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma
Study Start Date: Dec. 06, 2024
Study Type: INTERVENTIONAL
Condition:
Advanced Clear Renal Cell Carcinoma
Adult
Intervention:
BIOLOGICAL: IB-T101 injection
IB-T101 injection to treat advanced clear renal cell carcinoma
Recruitment Status: RECRUITING
Sponsor: Grit Biotechnology
Published by HT D...